Literature DB >> 6895662

Effects of 1,25-dihydroxyvitamin-D3 on renal function, mineral balance, and growth in children with severe chronic renal failure.

J C Chan, M B Kodroff, D M Landwehr.   

Abstract

To confirm and extend previous observations of enhanced linear growth in children with chronic renal disease being treated with 1,25-dihydroxyvitamin-D3 and to characterize further the calcium, phosphorus, magnesium, and zinc disorders in renal failure, 11 children (mean age 8 +/- 5 years) with chronic renal insufficiency (glomerular filtration rate 18% +/- 13% of normal) were evaluated on the basis of their reciprocal serum creatinine concentrations, height-velocity curves, mineral balances, and radiologic findings. Reciprocal serum creatinine concentrations analyzed retrospectively and prospectively during 32 months of 1,25-dihydroxyvitamin-D3 therapy showed progression of renal failure at rates linearly identical with those before treatment, thus suggesting that the treatment did not accelerate the rate of deterioration of glomerular filtration rate in chronic anal insufficiency. Indeed, one patient manifested a lesser decline in renal function (P less than .05). The height velocity of six of the children (75%) less than 12 years of age improved markedly over that expected for chronologic and bone ages after one year of treatment with orally administered 1,25-dihydroxyvitamin-D3, 15 to 35 ng/kg/day. All other medications except vitamin D2 were continued at their pretreatment dosage levels throughout the study. Growth velocity was unimproved in two of three children older than 12 years at the initiation of 1,25-dihydroxyvitamin-D3 therapy. Mineral balance data showed significant retention of calcium, phosphorus, magnesium, and zinc (357 +/- 32 mg/sq m/day, 250 +/- 82 mg/sq m/day, 38 +/- 32 mg/sq m/day, and 1,157 +/- 283 microgram/sq m/day, respectively), after treatment for 12 months. In addition, serum calcium, alkaline phosphatase, and parathyroid hormone concentrations returned toward normal. Finally, healing of renal osteodystrophy was radiologically evident after six months of therapy.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 6895662

Source DB:  PubMed          Journal:  Pediatrics        ISSN: 0031-4005            Impact factor:   7.124


  9 in total

Review 1.  Chronotherapy of high-dose active Vitamin D(3): is evening dosing preferable?

Authors:  Cheryl P Sanchez
Journal:  Pediatr Nephrol       Date:  2004-07       Impact factor: 3.714

2.  Phylloquinone and vitamin D status: associations with incident chronic kidney disease in the Framingham Offspring cohort.

Authors:  Conall M O'Seaghdha; Shih-Jen Hwang; Rachel Holden; Sarah L Booth; Caroline S Fox
Journal:  Am J Nephrol       Date:  2012-06-20       Impact factor: 3.754

3.  25-hydroxyvitamin D levels, race, and the progression of kidney disease.

Authors:  Michal L Melamed; Brad Astor; Erin D Michos; Thomas H Hostetter; Neil R Powe; Paul Muntner
Journal:  J Am Soc Nephrol       Date:  2009-10-29       Impact factor: 10.121

Review 4.  Minimizing bone abnormalities in children with renal failure.

Authors:  Helena Ziólkowska
Journal:  Paediatr Drugs       Date:  2006       Impact factor: 3.022

5.  Clinical practice recommendations for treatment with active vitamin D analogues in children with chronic kidney disease Stages 2-5 and on dialysis.

Authors:  Rukshana Shroff; Mandy Wan; Evi V Nagler; Sevcan Bakkaloglu; Mario Cozzolino; Justine Bacchetta; Alberto Edefonti; Constantinos J Stefanidis; Johan Vande Walle; Gema Ariceta; Günter Klaus; Dieter Haffner; Claus Peter Schmitt
Journal:  Nephrol Dial Transplant       Date:  2017-07-01       Impact factor: 5.992

Review 6.  Vitamin D deficiency and toxicity in chronic kidney disease: in search of the therapeutic window.

Authors:  Uwe Querfeld; Robert H Mak
Journal:  Pediatr Nephrol       Date:  2010-06-22       Impact factor: 3.714

Review 7.  Pubertal development in children with chronic kidney disease.

Authors:  Dieter Haffner; Miroslav Zivicnjak
Journal:  Pediatr Nephrol       Date:  2016-07-27       Impact factor: 3.714

8.  Long-term suppression of hyperparathyroidism by phosphate binders in uremic children.

Authors:  K Tamanaha; R H Mak; S P Rigden; C Turner; K M Start; G B Haycock; C Chantler
Journal:  Pediatr Nephrol       Date:  1987-04       Impact factor: 3.714

Review 9.  Secondary hyperparathyroidism in children with chronic renal failure: pathogenesis and treatment.

Authors:  Cheryl P Sanchez
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.